Dyne Therapeutics Income Statement (2019-2026) | DYN

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
23.87M36.51M42.30M28.24M46.66M34.67M33.19M37.54M59.13M55.25M58.84M44.54M62.26M92.80M81.81M106.45M99.24M97.22M95.43M100.89M
Selling, General & Administrative (Quarter)
6.29M6.26M9.66M7.55M6.09M7.61M6.96M7.93M7.61M7.02M8.84M24.62M9.70M12.86M15.30M15.93M16.55M16.67M20.70M24.39M
Other Operating Expenses (Quarter)
-0.01M-0.03M0.01M-0.01M-0.02M-0.22M-0.37M-0.13M-0.70M0.51M-0.19M-0.74M-0.03M-0.09M-1.60M0.28M-0.29M-0.13M
Operating Expenses (Quarter)
30.16M42.77M51.96M35.78M52.76M42.28M40.15M45.46M66.74M62.27M67.69M69.16M71.96M105.66M97.11M122.37M115.79M113.89M116.13M125.28M
Operating Income (Quarter)
-30.16M-42.77M-51.96M-35.78M-52.76M-42.28M-40.15M-45.46M-66.74M-62.27M-67.69M-69.16M-71.96M-105.57M-97.11M-122.37M-115.79M-113.89M-116.13M-125.28M
EBIT (Quarter)
-30.16M-42.77M-51.96M-35.78M-52.76M-42.28M-40.15M-45.46M-66.74M-62.27M-67.69M-69.16M-71.96M-105.57M-97.11M-122.37M-115.79M-113.89M-116.13M-125.28M
Non-operating items
Interest & Investment Income (Quarter)
0.21M0.18M0.18M0.23M0.44M0.90M1.34M1.49M2.21M2.19M1.75M3.00M7.05M9.28M7.59M7.10M6.62M8.48M7.66M8.76M
Other Non Operating Income (Quarter)
0.21M0.18M0.17M0.20M0.45M0.89M1.32M1.28M1.83M2.06M1.05M3.51M6.86M8.53M7.57M7.01M4.93M5.85M4.17M4.42M
Non Operating Income (Quarter)
0.21M0.18M0.17M0.20M0.45M0.89M1.32M1.28M1.83M2.06M1.05M3.51M6.86M8.53M7.57M7.01M4.93M5.85M4.17M4.42M
Net income details
EBT (Quarter)
-29.95M-42.58M-51.78M-35.55M-52.31M-41.38M-38.80M-43.97M-64.53M-60.08M-65.94M-66.16M-64.91M-96.29M-89.52M-115.27M-109.26M-108.32M-108.47M-116.52M
Profit After Tax (Quarter)
-29.95M-42.58M-51.79M-35.58M-52.30M-41.38M-38.83M-44.19M-64.90M-60.21M-66.64M-65.65M-65.10M-97.12M-89.54M-115.36M-110.86M-108.04M-111.95M-120.85M
Income from Continuing Operations (Quarter)
-29.95M-42.58M-51.78M-35.55M-52.31M-41.38M-38.80M-43.97M-64.53M-60.08M-65.94M-66.16M-64.91M-96.29M-89.52M-115.27M-109.26M-108.32M-108.47M-116.52M
Consolidated Net Income (Quarter)
-29.95M-42.58M-51.78M-35.55M-52.31M-41.38M-38.80M-43.97M-64.53M-60.08M-65.94M-66.16M-64.91M-96.29M-89.52M-115.27M-109.26M-108.32M-108.47M-116.52M
Income towards Parent Company (Quarter)
-29.95M-42.58M-51.78M-35.55M-52.31M-41.38M-38.80M-43.97M-64.53M-60.08M-65.94M-66.16M-64.91M-96.29M-89.52M-115.27M-109.26M-108.32M-108.47M-116.52M
Net Income towards Common Stockholders (Quarter)
-29.95M-42.58M-51.78M-35.55M-52.31M-41.38M-38.80M-43.97M-64.53M-60.08M-65.94M-66.16M-64.91M-96.29M-89.52M-115.27M-109.26M-108.32M-108.47M-116.52M
Additional items
EPS (Basic) (Quarter)
-0.58-0.83-1.01-0.69-1.01-0.80-0.73-0.78-1.08-0.99-1.09-0.81-0.70-0.96-0.88-1.05-0.97-0.76-0.73-0.73
EPS (Weighted Average and Diluted) (Quarter)
-0.58-0.83-1.01-0.69-1.01-0.80-0.73-0.78-1.08-0.99-1.09-0.81-0.70-0.96-0.88-1.05-0.97-0.76-0.73-0.73
Shares Outstanding (Weighted Average) (Quarter)
51.22M50.68M50.90M51.60M51.64M51.80M51.98M56.33M58.09M59.11M59.68M81.04M92.51M100.88M94.14M109.91M111.90M121.98M128.44M165.04M
Shares Outstanding (Diluted Average) (Quarter)
51.32M50.90M51.60M51.68M51.80M51.98M56.33M58.09M61.11M59.68M81.04M86.78M91.51M94.14M109.91M113.87M141.81M128.44M165.04M
EBITDA (Quarter)
-29.93M-42.58M-52.02M-36.24M-52.53M-41.21M-38.41M-43.82M-64.75M-60.17M-66.62M-65.78M-65.21M-96.41M-90.01M-115.13M-110.85M-107.80M-111.98M-121.47M
Interest Expenses (Quarter)
0.09M2.90M
Shares Outstanding (Quarter)
51.23M51.48M51.57M51.65M51.73M51.91M55.64M58.31M61.01M61.32M61.47M87.09M100.12M101.75M102.32M113.63M114.34M142.61M164.95M165.20M